DocG DocG | AI-Powered Clinical Summaries
Sign In

Stay Current with Medical Literature

AI-powered clinical summaries delivered to your inbox 3 times per week. Evidence-based insights in 300 words, designed for busy physicians.

Sign Up

See What You Get

Subscribers receive email summaries and access to our interactive AI-powered article rankings.

Email Summary Example

High-risk patients benefit most from saturated fat changes
Reducing saturated fat shows little benefit in low-risk adults, but may reduce deaths and heart attacks in high-risk adults, especially when replaced with polyunsaturated fat.
*Systematic review of randomized trials; Level 1a (OCEBM).

Citation

Steen JP, Klatt KC, Chang Y, et al. Effect of interventions aimed at reducing or modifying saturated fat intake on cholesterol, mortality, and major cardiovascular events: a risk-stratified systematic review of randomized trials. Annals of Internal Medicine. 2026;179:242-255. doi:10.7326/ANNALS-25-02229.

Background

Advice to lower saturated fat remains debated because it clearly lowers cholesterol, but its impact on deaths and major heart and stroke events is less certain. This review focused on long-term randomized trials and reported results by baseline heart risk.

Patients

Adults (18+) with or without prior heart disease. Exclusions: acute illness, pregnancy or breastfeeding, and trials where >20% had active cancer or unrelated chronic illness.

Intervention

Diet advice and/or provided foods or oils to reduce saturated fat or replace it with other nutrients, intended duration ≥2 years.

Control

Usual diet or higher saturated fat intake.

Outcome

All-cause death, cardiovascular death, nonfatal heart attack, stroke, total cholesterol, “bad” cholesterol (LDL).

Follow-up Period

Last trial follow-up (about 4–5 years); absolute effects standardized to 5 years.

Results

Outcome Key finding
Total cholesterol Lowered by 0.34 mmol/L on average (14 trials).
“Bad” cholesterol (LDL) Lowered by 0.15 mmol/L on average (6 trials).
Nonfatal heart attack (primary) When saturated fat was replaced mainly with polyunsaturated fat: risk ratio 0.75 (6 trials); in high-risk adults, about 21 fewer events per 1000 over 5 years (number needed to treat ≈48).
Across all trials combined, effects on deaths, stroke, and nonfatal heart attack were not clearly different from no effect; estimated benefits were more meaningful in high-risk than low-risk groups.

Limitations

Many trials were older and at higher risk of bias, and diets varied widely in what replaced saturated fat and in how well participants actually changed intake. Limited data compared replacement with monounsaturated fat or protein.

Funding

None reported.

Clinical Application

For high cardiovascular risk patients, prioritize replacing saturated fat with polyunsaturated fat foods; for low-risk patients, expect minimal event reduction and focus on overall diet quality.

Top Journal Rankings - May 2026

611 abstracts scored across 7 criteria. Click any article to expand criterion scores.
1. 8.5
Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.
Overall: A large randomized trial in ASCVD patients found fewer major cardiovascular events over 3 years with an LDL target <55 mg/dL versus <70 mg/dL and similar reported safety, making the finding both clinically meaningful and readily actionable despite the open-label design and composite endpoint including procedure-driven components.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 8.0
Secondary prevention for established ASCVD and LDL target selection are common outpatient decisions that primary-care clinicians co-manage, though medication intensification and target achievement may sometimes be specialist-led.
Validity, Bias Control & Precision 8.0
Randomized superiority trial with ~3000 participants and 3-year follow-up; effect estimate is supported by a reported HR with 95% CI. Open-label design raises some risk of performance/detection bias, especially with revascularization and hospitalization components.
Patient-Oriented Outcomes 8.0
Primary endpoint includes clinically meaningful events (CV death, MI, stroke, unstable angina hospitalization) but is a composite that also includes revascularization, which is more clinician-driven and potentially bias-prone in an unblinded trial.
Magnitude of Net Benefit 8.0
Absolute event reduction is ~3.1% over 3 years (6.6% vs 9.7%) with HR 0.67; safety outcomes were largely similar between groups, suggesting a favorable net benefit on a patient-relevant composite.
Implementability & Practicality 9.0
Treat-to-target LDL strategies are familiar and implementable with routine lipid monitoring; however, achieving <55 mg/dL may require more intensive therapy and follow-up than <70 mg/dL.
Practice-Changing Potential 10.0
Provides direct randomized trial evidence comparing two guideline-relevant LDL targets for ASCVD with improved clinical outcomes and similar safety, which could directly influence target selection in routine secondary prevention.
2. 8.0
Maternal RSV vaccination for infant protection: A systematic review and meta-analysis of phase 3 trials with an integrated economic evaluation.
Overall: A large RCT-only meta-analysis shows maternal RSV vaccination reduces infant RSV (including severe disease) without clear major pregnancy harms, with moderate-to-high certainty and policy-relevant economic modeling, though absolute benefit is moderate and cost may constrain implementation.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 8.5
Addresses maternal vaccination during pregnancy to prevent infant RSV outcomes—highly relevant to routine prenatal/primary care counseling and immunization workflows, with broad policy and outpatient applicability.
Validity, Bias Control & Precision 8.5
Systematic review/meta-analysis restricted to phase 3 RCTs (4 trials; n=17,391), with duplicate screening/extraction, RoB-2 assessment, GRADE, and CIs reported; random-effects pooling is appropriate, though details on heterogeneity/publication bias are not provided in the abstract.
Patient-Oriented Outcomes 8.0
Reports clinically meaningful infant outcomes (RSV infection and severe disease) and key maternal/fetal safety outcomes (preterm birth, pre-eclampsia, stillbirth); hospitalization is not explicitly reported, but severity outcomes are still patient-important.
Magnitude of Net Benefit 7.0
Relative benefits are substantial (RR 0.47 for any RSV; RR 0.36 for severe disease), but absolute benefit appears modest (NNV 85–127). No increased major pregnancy risks were observed, supporting a favorable benefit–harm profile.
Implementability & Practicality 7.5
Vaccination in pregnancy is operationally feasible in outpatient prenatal care, but the abstract highlights substantial pricing/cost barriers (e.g., list price US$295) and reliance on public-sector pricing for better cost-effectiveness, which may limit real-world uptake.
Practice-Changing Potential 8.5
Synthesizes phase 3 RCT evidence with moderate-to-high certainty and includes safety plus economic modeling, supporting programmatic decisions and likely influencing guidelines/implementation where maternal RSV vaccination is under consideration.
3. 7.9
Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.
Overall: A very large IPD meta-analysis of RCTs shows consistent, precise relative reductions in major cardiovascular events from BP lowering across CKD stages, supporting broadly applicable outpatient management, though the abstract lacks absolute benefits and harms to fully quantify net impact and the main new nuance is reduced relative benefit in CKD with diabetes.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 8.0
Blood-pressure management in CKD is a common outpatient decision, and the analysis spans CKD stages and key subgroups relevant to generalist care, though advanced CKD often involves shared specialty management.
Validity, Bias Control & Precision 9.5
Large individual-participant-data meta-analysis of randomized trials (285,124 participants) with prespecified subgroup analyses, time-to-event methods, and tight confidence intervals supports high credibility and precision.
Patient-Oriented Outcomes 8.5
Primary endpoint is a major cardiovascular events composite including fatal/non-fatal stroke and ischemic heart disease plus heart-failure hospitalization/death, which are clinically meaningful patient outcomes.
Magnitude of Net Benefit 6.0
Benefits are statistically clear but modest per 5 mm Hg systolic reduction (HR ~0.90–0.91), with no absolute risk reductions or adverse effects/burden reported in the abstract to judge net benefit fully.
Implementability & Practicality 8.5
BP lowering uses standard antihypertensive drug classes and routine monitoring, making the findings broadly actionable in outpatient practice, including for CKD patients.
Practice-Changing Potential 7.0
The results strengthen confidence that BP lowering benefits extend across CKD severity and may influence thresholds and discussions, while the noted attenuation in CKD with diabetes is important but not directly directive without absolute effects or specific alternative strategies.
4. 7.8
Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.
Overall: A large randomized noninferiority trial suggests that discontinuing beta-blockers beyond 1 year after MI in stable patients without heart failure is not worse for major clinical outcomes and is easy to implement, though open-label design and generalizability limits keep the practice impact short of definitive for all settings.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 7.5
Addresses a common long-term secondary-prevention decision after MI (whether to continue beta-blockers beyond 1 year) that often affects outpatient and shared-care management, though the enrolled population and conduct were cardiology-centered and limited to South Korea.
Validity, Bias Control & Precision 8.5
Large multicenter randomized noninferiority trial (n=2540) with multi-year follow-up and reported hazard ratio with 95% CI; open-label design and use of a composite endpoint introduce some risk of bias, but key methods and precision are reasonably strong for the abstract.
Patient-Oriented Outcomes 8.5
Primary outcome includes all-cause death, recurrent MI, and heart-failure hospitalization, which are clearly patient-important; serious adverse events were also reported.
Magnitude of Net Benefit 6.0
Discontinuation was noninferior with numerically fewer primary events (7.2% vs 9.0%), but the CI includes possible meaningful harm or benefit and there is no demonstrated superiority; harms (serious adverse events) appeared similar, and medication-burden reduction is plausible but not quantified.
Implementability & Practicality 9.0
Stopping a beta-blocker after a defined stability period is simple to operationalize in routine outpatient care without specialized equipment, though it still requires clinical follow-up and individualized deprescribing.
Practice-Changing Potential 7.5
A large NEJM randomized trial directly supports deprescribing in a clearly defined post-MI subgroup (LVEF ≥40% and no heart failure) and could influence guidelines and routine care, but generalizability (e.g., low proportion of women and single-country setting) and the noninferiority framework temper immediate universal change.
5. 7.8
Coadministered Influenza- and Pertussis-Containing Vaccines in Pregnant Women.
Overall: A large matched registry-based cohort provides fairly strong reassurance that concomitant influenza and pertussis vaccination in pregnancy is not associated with worse maternal or neonatal outcomes, supporting practical same-day vaccination in routine care despite limitations of nonrandomized design.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 8.5
Addresses a common prenatal care decision (whether to give influenza and pertussis vaccines on the same day) with outcomes relevant to routine outpatient maternity/primary care workflows.
Validity, Bias Control & Precision 7.0
Large, population-based matched cohort with linked registries and adjusted analyses, but retrospective and nonrandomized with potential residual confounding; CIs are reasonably informative for key outcomes.
Patient-Oriented Outcomes 9.0
Primary and secondary outcomes (preterm birth, stillbirth, small for gestational age, low birth weight, hemorrhage, preeclampsia/eclampsia) are directly patient- and infant-important rather than surrogate markers.
Magnitude of Net Benefit 6.0
Findings are mainly reassurance of no increased adverse outcome rates; confidence intervals still allow for modest differences, and the study does not measure benefits like increased vaccination uptake or reduced influenza/pertussis morbidity.
Implementability & Practicality 9.0
Same-day coadministration is straightforward using existing vaccines and typical prenatal visit timing (≥20 weeks), with minimal added workflow burden compared with separate visits.
Practice-Changing Potential 7.0
Could meaningfully increase clinician confidence and support consolidating vaccinations into fewer visits, but as observational evidence showing safety (not improved clinical outcomes), guideline-level change may still rely on broader corroboration.
6. 7.8
Acute Care Use and Mortality by Tele-Emergency Care Use, Modality, and Clinician Type.
Overall: A very large VA observational evaluation suggests tele-emergency visits after nurse-line triage are associated with substantially fewer short-term ED visits (especially for emergent calls) without mortality differences, with strong precision but residual-confounding limits and incomplete reporting of harms/burden.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 7.5
Addresses triage and management of acute symptoms via a nurse advice line with downstream ED use—highly relevant to first-contact care decisions, though studied within the VA and during business hours.
Validity, Bias Control & Precision 7.5
Large, national multicenter cohort with propensity-score weighting and difference-in-differences modeling plus tight confidence intervals, but still observational and vulnerable to residual confounding and implementation-related biases.
Patient-Oriented Outcomes 8.0
Includes clinically meaningful outcomes (ED visit, hospitalization, and 30-day mortality), not just surrogate process measures.
Magnitude of Net Benefit 8.5
Shows a large absolute reduction in 7-day ED visits among those receiving tele-emergency care (28.5% vs 45.0%; -16.5%) with similar hospitalization associations and no mortality difference reported; harms and patient burden are not described in the abstract.
Implementability & Practicality 7.0
Tele-emergency care by phone/video is feasible for many systems, but real-world rollout requires staffing, workflows, and technology access; these operational details and patient-level friction are not detailed.
Practice-Changing Potential 8.0
If causal, the large reduction in ED utilization for high-acuity triage calls could meaningfully change acute-care pathways, though the observational design and small facility-level effect temper certainty for broad practice change.
7. 7.7
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.
Overall: A large, double-blind randomized trial secondary analysis suggests oral semaglutide may reduce clinically important HF events in people with type 2 diabetes who already have heart failure, with similar serious adverse events, but subgroup/secondary-analysis limitations and missing absolute-effect details reduce certainty about the size and generalizability of benefit.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 7.5
Addresses a very common primary-care condition (type 2 diabetes) and clinically important comorbidity (heart failure), but the trial population is higher-risk (ASCVD and/or CKD) and the analysis is subgroup-based (with vs without baseline HF), which may limit generalizability to lower-risk primary-care populations.
Validity, Bias Control & Precision 8.5
Large, double-blind, placebo-controlled randomized trial with long follow-up and reported hazard ratios with confidence intervals. However, this is a secondary analysis and relies on subgroup findings with an interaction P value near conventional thresholds (P=0.06), which increases the risk of chance findings.
Patient-Oriented Outcomes 8.5
Primary assessed outcome is a clinical composite including heart failure hospitalization, urgent HF visit, and cardiovascular death—outcomes that matter directly to patients. MACE is also patient-important.
Magnitude of Net Benefit 6.5
In participants with baseline HF, the composite HF outcome was reduced (HR 0.78; 95% CI 0.63–0.96), suggesting a modest-to-moderate relative benefit; effects differed by HF subtype (more favorable for preserved EF). Absolute risk reductions and treatment burden details are not provided; serious adverse events were similar between groups.
Implementability & Practicality 7.5
Once-daily oral semaglutide is a practical outpatient intervention and aligns with existing diabetes workflows, but real-world implementation may involve cost/access barriers and titration/monitoring considerations that are not addressed in the abstract.
Practice-Changing Potential 7.5
Suggests clinically meaningful HF event reduction specifically among patients with T2D and existing HF, which could influence drug selection in high-risk patients. Still, being a secondary/subgroup analysis (and with uncertain differential benefit by HF subtype) may temper immediate, broad practice change.
8. 7.7
Behaviorally Informed Text Messaging to Promote Colon Cancer Screening: A Quality Improvement Randomized Clinical Trial.
Overall: A pragmatic randomized trial in safety-net primary care shows automated behavioral text reminders meaningfully increase FIT completion versus nurse calls, with strong feasibility but outcomes limited to screening completion rather than clinical endpoints.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
Targets colorectal cancer screening uptake using FIT in Federally Qualified Health Centers, a common, high-priority primary-care preventive care workflow.
Validity, Bias Control & Precision 8.0
Randomized comparison with a clear comparator and objective EHR-ascertained outcome; fairly large sample with a reported absolute effect and 95% CI, though unblinded and short follow-up.
Patient-Oriented Outcomes 4.0
Outcome is FIT completion (a process measure) rather than downstream patient outcomes such as cancer incidence, stage at diagnosis, or mortality.
Magnitude of Net Benefit 8.0
Shows a clinically meaningful absolute increase in completion (9.0 percentage points; 95% CI 3.6–14.5) with low apparent patient burden and potential staff-burden reduction.
Implementability & Practicality 9.0
Automated one-way texting is scalable and low-touch compared with nurse calls, requiring minimal added clinic time once infrastructure is in place.
Practice-Changing Potential 8.0
Provides pragmatic randomized evidence that automated texts can outperform nurse-call reminders for FIT completion, supporting a feasible change in outreach strategy in similar settings.
9. 7.7
Asundexian for Secondary Stroke Prevention.
Overall: This large, well-conducted phase 3 trial reports a precise, patient-important reduction in recurrent ischemic stroke with similar major bleeding, yielding a likely clinically meaningful but not dramatic net benefit that may change secondary prevention practice if access and guideline adoption follow.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 6.5
Secondary prevention after ischemic stroke/TIA is clinically important for generalists, but enrollment within 72 hours and antiplatelet strategy decisions are often initiated in hospital/specialty care, with primary care more involved in longer-term continuation.
Validity, Bias Control & Precision 9.5
Large phase 3 randomized double-blind placebo-controlled trial (n=12,327) with clear endpoints and precise effect estimates (HR 0.74; 95% CI 0.65–0.84).
Patient-Oriented Outcomes 9.0
Primary outcome (ischemic stroke) and key secondary composite including cardiovascular death/MI/stroke, plus major bleeding safety, are directly patient-important outcomes.
Magnitude of Net Benefit 7.0
Absolute ischemic stroke reduction was 2.2% (6.2% vs 8.4%), with similar major bleeding (1.9% vs 1.7%; CI includes harm and benefit), suggesting a modest but meaningful net benefit with low added burden.
Implementability & Practicality 6.5
Once-daily oral add-on to antiplatelet therapy is straightforward, but as a new agent it likely entails cost/formulary and coordination with post-stroke care plans.
Practice-Changing Potential 7.5
A large NEJM phase 3 trial showing fewer recurrent strokes without an apparent major-bleeding penalty could influence secondary prevention strategies, though uptake will depend on guidelines, access, and longer-term real-world experience.
10. 7.7
Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage.
Overall: A large, well-controlled trial shows that adding a low-dose triple antihypertensive pill after intracerebral hemorrhage reduces recurrent stroke and major cardiovascular events, with some trade-off in tolerability and monitoring needs.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 7.0
Blood-pressure management and secondary stroke prevention are highly relevant to outpatient care, though the population (post–intracerebral hemorrhage) is often co-managed with neurology/stroke specialists.
Validity, Bias Control & Precision 8.5
Multinational double-blind randomized placebo-controlled trial with a large sample (n=1670) and time-to-event analysis with confidence intervals; the active run-in may select for tolerators and reduce generalizability.
Patient-Oriented Outcomes 9.0
Primary outcome was recurrent stroke, with additional major cardiovascular events and safety outcomes, all directly patient-important.
Magnitude of Net Benefit 6.5
Recurrent stroke was reduced (4.6% vs 7.4%; HR 0.61) and major cardiovascular events were lower, but treatment discontinuation due to adverse events was notably higher (13.6% vs 6.0%), largely due to creatinine increases.
Implementability & Practicality 7.5
A once-daily fixed-dose combination is straightforward to prescribe, but requires renal function monitoring and tolerability management, and availability of the specific combination pill may affect real-world uptake.
Practice-Changing Potential 7.5
Demonstrates a clinically meaningful reduction in recurrent stroke in a high-risk group using a simple regimen, though higher discontinuation and the run-in design may temper immediate universal adoption.
Score Guide: 9-10 Exceptional 7-8 Strong 5-6 Moderate 3-4 Weak 1-2 Poor
Showing top 10 of 611

How It Works

1

Sign Up with Google

Create your account in seconds using your Google account. No passwords to remember.

2

Receive Email Summaries

Get AI-curated clinical summaries delivered to your inbox three times per week (Monday, Wednesday, Friday).

3

Find the Best New Articles

Our interactive article rankings allow you to find the best articles, tailored to you.

Ready to Stay Current?

Sign Up